Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Heart J. 2014 May 21. pii: ehu213. [Epub ahead of print]

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.

Author information

  • 1Erasmus University Medical Center, Rotterdam, The Netherlands.
  • 2Herzzentrum Universität Leipzig, Strumpelstrasse 39, Leipzig 4289, Germany.
  • 3Guy's and St. Thomas' Hospital, London, UK.
  • 4San Raffaele Scientific Institute, Milan, Italy.
  • 5Medical City Hospital, Dallas, TX, USA.
  • 6Institut Hospitalier Jacques Cartier, Générale de santé, Massy, France.
  • 7May Clinic Rochester, Rochester, MN, USA.
  • 8Evanston Hospital, Evanston, IL, USA.
  • 9University Hospital Uppsala, Uppsala, Sweden.
  • 10Boston Scientific Corporation, Natick, MA, USA.
  • 11Herzzentrum Universität Leipzig, Strumpelstrasse 39, Leipzig 4289, Germany mohrf@medizin.uni-leipzig.de.

Abstract

AIMS:

Coronary artery bypass grafting (CABG) has been considered the standard of care for patients with three-vessel disease (3VD), but long-term comparative results from randomized trials of CABG vs. percutaneous coronary intervention (PCI) using drug-eluting stents (DES) remain limited.

METHODS AND RESULTS:

Patients with de novo 3VD or left main disease were randomly assigned to PCI with the paclitaxel-eluting first-generation stent or CABG in the SYNTAX trial. This pre-specified analysis presents the 5-year outcomes of patients with 3VD (n = 1095). The rate of major adverse cardiac and cerebrovascular events (MACCE) was significantly higher in patients with PCI compared with CABG (37.5 vs. 24.2%, respectively; P < 0.001). Percutaneous coronary intervention as opposed to CABG resulted in significantly higher rates of the composite of death/stroke/myocardial infarction (MI) (22.0 vs. 14.0%, respectively; P < 0.001), all-cause death (14.6 vs. 9.2%, respectively; P = 0.006), MI (9.2 vs. 4.0%, respectively; P = 0.001), and repeat revascularization (25.4 vs. 12.6%, respectively; P < 0.001); however, stroke was similar between groups at 5 years (3.0 vs. 3.5%, respectively; P = 0.66). Results were dependent on lesion complexity (P for interaction = 0.12); in patients with a low (0-22) SYNTAX score, PCI vs. CABG resulted in similar rates of MACCE (33.3% vs. 26.8%, respectively; P = 0.21) but significantly more repeat revascularization (25.4% vs. 12.6%, respectively; P = 0.038), while in intermediate (23-32) or high (≥33) SYNTAX score terciles, CABG demonstrated clear superiority in terms of MACCE, death, MI, and repeat revascularization. Differences in MACCE between PCI and CABG were larger in diabetics [hazard ratio (HR) = 2.30] than non-diabetics (HR = 1.51), although the P for interaction failed to reach significance for MACCE (P for interaction = 0.095) or any of the other endpoints.

CONCLUSION:

Five-year results of patients with 3VD treated with CABG or PCI using the first-generation paclitaxel-eluting DES suggest that CABG should remain the standard of care as it resulted in significantly lower rates of death, MI, and repeat revascularization, while stroke rates were similar. For patients with low SYNTAX scores, PCI is an acceptable revascularization strategy, although at a price of significantly higher rates of repeat revascularization.

CLINICAL TRIAL REGISTRATION:

NCT00114972.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.

KEYWORDS:

Coronary artery bypass grafting; Diabetes; Incomplete revascularization; Percutaneous coronary intervention; Randomized trial; SYNTAX; Three-vessel disease

PMID:
24849105
[PubMed - as supplied by publisher]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk